Hand-held Gamma Camera in the SNOLL Procedure (TRECAM)

July 29, 2019 updated by: Assistance Publique - Hôpitaux de Paris

Contribution of a Hand-held Gamma Camera (TreCam) to the SNOLL(Occult Breast Lesion Localization Plus Sentinel Node Biopsy) Procedure in Breast Cancer

In France, breast cancer affects approximately 53,000 new cases per year. The investigators have to take care more and more women with subclinical lesions (nonpalpable), and it represents around 25% to 35% of the diagnosed breast cancers. The main problem of the surgical management of these lesions is the quality of preoperative identification which determines the quality of surgery and oncological and cosmetic outcomes. For this type of lesion, SNOLL (Sentinel Node and Occult Lesion Localization) procedure could be proposed. This is a radioactive labeling of the tumor site and sentinel lymph node (SLN). The investigators want to evaluate the potential benefits of using a hand held camera called TreCam in this SNOLL procedure. This camera permits to obtain nuclear imaging at the bedside and in the operating theater.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Hypothesis:

The use of intraoperative TReCam improves the surgical procedure by providing relevant information during surgery to reduce the rate of further surgery for inappropriate margins.

Main Objective:

Evaluation of the contribution of TreCam in SNOLL procedure.

Main endpoint:

The rate of further surgery for inappropriate margins of the lumpectomy (less than 3mm)

Second endpoint:

Lumpectomy's characteristics, Cosmetics results Number of SLNs detected with TreCam at the different times of the procedure. Operative duration

Plan experimental :

Multicentric (3 centers) Phase II randomized non comparative study. All patients with non-palpable invasive cancer histologically proven and with ultrasound target will have SNOLL procedure.

Patients will be randomized preoperatively into two groups. Group 1: patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.

Group 2: patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.

In group 1:

  • Day-1: Injection of Tc99m (Nanocis) in contact with the tumor under ultrasound guidance followed by a lymphoscintigraphy (LS): Localization and counting of the radioactive SLNs. Localization of the tumor site.
  • Day 0: Before incision, exploration with the classic gamma probe (GP) for the localization of the different surgical areas (breast and axillary) is performed. Removal of SLN is achieved thanks to double detection (colorimetric and radioactive). After incision, radioactive SLN are identified by GP. At the end of the SLN procedure, the operator checks the absence of residual activity and controls with preoperative LS. In case of non detection of SLN or metastases identified during extemporaneous examination an axillary node dissection is performed. The GP is also used to guide lumpectomy and verify the absence of significant residual radioactivity after lumpectomy. Extemporaneous examination of lumpectomy specimen (size, limits of resection) is performed. Additional shaving of the cavity margins is appreciated by the surgeon.

In group 2 :

TReCam is used at different stages of SNOLL procedure:

  • Day-1: A mapping with TReCam is performed after LS. (without LS results)

  • Day 0: Before incision, in addition to GP, TReCam is used to define number and localization of SLN and the tumor site.

    • At the end of the usual SLN procedure, axillary area is also explored by TReCam in order to find residual SLN.
    • After lumpectomy, absence of significant residual radioactivity is checked by GP and TReCam
    • Operative duration will be reported.
    • Difficulties in data acquisition with TReCam.
    • Collection of all the histological results.
    • Outcome: Cosmetic results, decision of further surgery for inappropriate margins.

Total duration study: 13 months: Inclusion period : 12 months; Follow up : 1 month

Statistics

  1. Sample size. This is a phase II 2-steps randomized non comparative study. N= 30 patients in each group. This will allow to test the potential interest of TReCAm in group 2 using an optimal II-stage design based on the number of patients without reintervention (success).

    The tested hypothesis are:

    H0: p=p0 avec p0 = 80% (poor technique) H1: p=p1>p0 avec p1 = 95% (good technique) N= 30 patients per group will be considered, method proposed by R.P. A'Hern (Stat Med 2001 :20. 859-866).

    The required power was set at 80% and the alpha risk was set at 5%.

  2. Strategy analysis of data collected

    Populations studied:

    The primary analysis will focus on all randomized patients (intention to treat analysis). Given the type of patients and the evaluation time of the primary endpoint, it is unlikely that there is lost sight. However, any patient with no information available on the primary endpoint will be classified as having a reoperation.

  3. Justification of statistical tests

Descriptive analysis:

All quantitative parameters will be summarized descriptively in each group of treatment modality and for each time they are collected. The analysis will include descriptive statistics for each quantitative parameter each time: average, standard deviation, minimum, maximum, median and quartiles, number of missing values. Qualitative parameters are expressed by the frequency distribution and accurate bilateral confidence intervals to 95% associated. (asymptotic estimators will not be used because of the considered effective).

Study Type

Interventional

Enrollment (Actual)

47

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Bondy, France, 93140
        • Service de gynécologie-Obstétrie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria :

  • Patients older than 18 years
  • Patients undergoing SNOLL procedure for breast non palpable invasive cancer (ultrasound image target) confirmed by biopsy before surgery
  • Clinical T0N0 stage
  • Before the SNOLL procedure, patients will be informed on all this procedure
  • A free and informed consent must be obtained

Exclusion Criteria :

  • Multifocal breast cancer, diffuse microcalcifications
  • Non-palpable breast cancer without ultrasound target
  • Isolated in situ cancer or invasive cancer associated with extended in situ carcinoma
  • Patients who underwent neoadjuvant chemotherapy
  • Palpable axillary nodes on clinical examination or with a suspicious or positive cytology
  • Pregnant patient
  • History of axillary surgery or mammoplasty
  • Allergy to any component of the tracking technique

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Group 1
Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.
Experimental: Group 2
Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.
Device: TRECAM
using the camera during the surgery
Other Names:
  • hand held Camera

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of further surgery for non in sano or inadequate (less than 3 mm security margins) lumpectomy piece's margins.
Time Frame: Between 2 and 3 weeks
Between 2 and 3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Size, volume and weight of the lumpectomy.
Time Frame: between 2 and 3 weeks
between 2 and 3 weeks
Status of resection margins
Time Frame: one day
During surgery
one day
Cosmetics results: 4 point Score
Time Frame: between 2 and 3 weeks
EXCELLENT: the treated breast is almost identical to untreated breast GOOD: minor difference between the treated breast and untreated breast. FAIR: obvious difference between the treated breast and untreated breast. POOR: major aesthetic and functional sequelae in the treated breast.
between 2 and 3 weeks
Morbidity
Time Frame: between 2 and 3 weeks
(hematoma, abscess...).
between 2 and 3 weeks
Volume of resection / tumor volume
Time Frame: between 2 and 3 weeks

Volume of resection / tumor volume:

(Length x width x height) specimen / (π / 6) d3.(d is the histological maximum diameter of the lesion) Length x width x height) specimen / (π / 6) d3.(d is the histological maximum diameter of the lesion
between 2 and 3 weeks
Duration of utilization of TreCam at The day before surgery and before induction of anesthesia for the location of the breast injection site and SLN.
Time Frame: 2 days
The day before surgery, and at the day of surgery
2 days
Duration of utilization of TreCam at at the end of the SLN procedure for verifying the absence of radioactivity.
Time Frame: One Day
Day of surgery
One Day
Duration of utilization of TreCam at each step of the procedure during the breast exploration before lumpectomy.
Time Frame: One day before the surgery
One day before the surgery
Duration of utilization of TreCam at at the end of lumpectomy for acquisition of images of the tumor's bed after removal of the radioactive target and for acquisition of image of the lumpectomy's specimen.
Time Frame: One day
Before surgery
One day
Difficulties in data acquisition Using a scale of 4 items : VERY EASY, EASY, DIFFICULT, IMPOSSIBLE
Time Frame: one day
one day
Comparison between imaging data provided in preoperative time by TreCam and by standard LS: image's quality, location of the injection's site, location and number of SLN.
Time Frame: One day
preoperative time
One day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

Centre National de la Recherche Scientifique, France

Investigators

  • Principal Investigator: Alexandre BRICOU, MD, Hôpital Jean Verdier

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 20, 2015

Primary Completion (Actual)

June 19, 2018

Study Completion (Actual)

June 19, 2018

Study Registration Dates

First Submitted

February 6, 2014

First Submitted That Met QC Criteria

March 27, 2014

First Posted (Estimate)

April 2, 2014

Study Record Updates

Last Update Posted (Actual)

July 31, 2019

Last Update Submitted That Met QC Criteria

July 29, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P120704

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe